TRUST ≈8 YEARS OF EXTENSIVE CLINICAL EXPERIENCE AND THE INTEGRITY OF DATA FROM LARGE, WELL–CONTROLLED TRIALS1
EYLEA is the #1 prescribed anti–VEGF FDA approved for Wet AMD, DME, and MEfRVO*
*IBM Truven MarketScan data: Number of injections administered from Q4 2017 through Q3 2018; data on file.
The Established Experience of EYLEA1,2
- ≈8 years of real–world experience1
- An estimated ≈9 million doses administered to ≈790,000 eyes since launch (and counting)1,2
- 8 phase 3 clinical trials including more than 3000 EYLEA–treated patients across all approved indications1
The flexibility of a broad range of indications, and dosing flexibility across several indications1
EYLEA 2 mg (0.05 mL) Dosing Schedule1
Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (≈ every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every–4–week (monthly) dosing after the first 20 weeks (5 months).